Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Xlife Sciences Ltd. ( (CH:XLS) ) has issued an update.
Xlife Sciences AG has published its half-year report for 2025, highlighting significant progress towards the NASDAQ listing of VERAXA Biotech AG, a key milestone for both companies. The report also outlines various international collaborations and developments, including a partnership in Korea and advancements in digital health and precision oncology. These efforts are part of Xlife Sciences’ strategy to internationalize its platform and prepare its portfolio companies for success in capital markets. Financially, the company reported a slight increase in revenue and equity, despite a decrease in cash and cash equivalents. The second half of 2025 will focus on supporting VERAXA’s NASDAQ listing, clinical implementations, and expanding presence in the USA, aiming to enhance value and global visibility.
More about Xlife Sciences Ltd.
Xlife Sciences AG is a Swiss incubator and accelerator that focuses on the development and commercialization of promising research projects in the life sciences sector. The company aims to bridge the gap between research and healthcare markets by selecting projects in technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health to advance their development and value.
Average Trading Volume: 1,967
Technical Sentiment Signal: Sell
Current Market Cap: CHF109.6M
For an in-depth examination of XLS stock, go to TipRanks’ Overview page.